Armando Orlandi Highlights Genomic Insights in HR+/HER2- Metastatic Breast Cancer
Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on LinkedIn about a paper by Letizia Pontolillo et al. published in npj | breast cancer:
“I’m proud to celebrate the groundbreaking publication in npj Breast Cancer by our PhD research student in Oncology at the University Hospital Foundation A. Gemelli, Dr Letizia Pontolillo, now under the distinguished mentorship of Prof. Massimo Cristofanilli, MD, FACP at Weill Cornell Medicine in New York!
Study Highlights
Multi-institutional analysis of 93 HR+/HER2- metastatic breast cancer patients post-CDK4/6i therapy
Key genomic alterations identified:
- PIK3CA: 37.6%
- ESR1: 46.2%
- TP53: 31.2%
Major clinical findings
- PTEN alterations predict worse prognosis (PFS p=0.008, OS p=0.006)
- ESR1 mutations significantly associated with CDK4/6i exposure (p<0.001)
- TP53 and CCND1 impact overall survival
- Low mutant allele frequency correlates with better outcomes
Clinical Impact
This study paves the way for precision medicine in the post-CDK4/6i setting, demonstrating again how ctDNA profiling can guide second-line therapeutic decisions in metastatic breast cancer.”
Title: Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR+/HER2- metastatic breast cancer: a retrospective multiinstitutional Consortium analysis
Authors: Letizia Pontolillo, Andrew A. Davis, Lorenzo Gerratana, Arielle J. Medford, Judy Wang, Eleonora Nicolo, Katherine Clifton, Marko Velimirovic, Surbhi Warrior, Emily Podany, Eleni Andreopoulou, Mara Serena Serafini, Laura Munoz-Arcos, Elisabetta Molteni, Marla Lipsyc-Sharf, Caterina Gianni, Nadia Bayou, Charles S. Dai, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Carolina Reduzzi, Massimo Cristofanilli
You can read the Full Article on npj | breast cancer.
More posts featuring Armando Orlandi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023